Core F ? Immune Function The Immune Function Core F provides broadly ranging support for immunological studies. Driven by investigator need, and a rapidly changing science environment, the Core currently offers multiplexed cytokine measurements, standard flow cytometric analysis as well as flow imaging, sorting of cell populations via flow cytometry and other methods, and ELISA, ELISPOT, and infrared imaging. The re-structuring of the Core in 2010 included a cooperative agreement with the Cancer Center Cytometry and Imaging Microscopy Facility to pool the equipment, harmonize services, and maintain formal access to CLIA-level flow cytometry. Drs. Scott Sieg and James Jacobberger have been working closely together as Co-directors and have used their complementary expertise to greatly enhance Core services. Dr. Sieg provides immunological expertise, functional assays, and biomarkers, especially in the context of HIV research; Dr. Jacobberger provides expertise on flow and image cytometry instrumentation, single-cell assays, and biomarker discovery, especially in the areas of cell cycle, apoptosis, and cell signaling. A major function of the Core is to collaborate with users to develop novel immunological assays. For example Core F, in collaboration with the Proteomics & Systems Biology Core G, is refining new flow cytometric assays for characterizing the phospho-proteome. This unique platform should open new avenues of research relevant to HIV pathogenesis, clinical evaluation, and treatment. A parallel effort is focused on developing multiple pathway signaling measurements on sub-populations of cells in unfractionated human samples (e.g., blood). The Core also interacts closely with the Clinical Core D for sample procurement. The Immune Function Core (F) is currently the one of the most heavily used of all the CWRU/UH CFAR cores and during this grant cycle the Core generated net revenues of $384,177. Program income has been steadily reinvested in the purchase of advanced instruments, such as multicolor flow cytometers, and reagents. For example in 2012, the Immune Function Core purchased a BD Fortessa ? a next generation analytical instrument ? with blue, green, red and violet lasers and filters optimized to measure fluorescent proteins. This instrument was subsequently upgraded to add a high throughput 96 well plate feed system thanks to a CFAR supplementary award. As part of the recruitment of Dr. Skaly, the CFAR will purchase a BD Biosciences FACSAria with 4 or 5 lasers and 18-color capability. The FACSAria will be maintained under BSLII conditions to permit sorting of HIV-infected cells. This state-of-the-art instrument will bring sorting capacity in line with our analytical capacities and create further opportunities for Core-Core interactions since it will be used to prepare samples for sequencing and proteomic analyses by Cores E and G.. The specifically aims of the Core follow: ? To provide access to instruments and assays to support CFAR programs. ? To develop validated assays and platforms for CFAR investigators. ? To provide consultation and training at all levels. The development of innovative new platforms, such as phospho-protein analyses, spearheaded by the Immune Function Core creates new opportunities for scientific investigation and competitive advantages by CFAR investigators. The Core will continue to promote interactions among CFAR investigators, meeting the needs of the CFAR Working Groups, and cooperating with the other CFAR Cores to provide access to cutting edge technologies.

Public Health Relevance

Core F Understanding of HIV immunology is important for vaccine development, disease pathogenesis and immune restoration in HIV disease. This core provides services to CFAR faculty who require access to flow cytometry and other methods for evaluating immune functions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-25
Application #
9690561
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
25
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Tomas, Myreen E; Mana, Thriveen S C; Wilson, Brigid M et al. (2018) Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 62:
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Sahmoudi, Karima; Abbassi, Hassan; Bouklata, Nada et al. (2018) Immune activation and regulatory T cells in Mycobacterium tuberculosis infected lymph nodes. BMC Immunol 19:33
Webel, Allison R; Moore, Shirley M; Longenecker, Chris T et al. (2018) Randomized Controlled Trial of the SystemCHANGE Intervention on Behaviors Related to Cardiovascular Risk in HIV+ Adults. J Acquir Immune Defic Syndr 78:23-33
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Eckard, Allison Ross; O'Riordan, Mary Ann; Rosebush, Julia C et al. (2018) Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth. Antivir Ther 23:315-324
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150

Showing the most recent 10 out of 539 publications